How did Myomo's revenue and expenses shift in Q4 2024?

Myomo's revenue and expenses in Q4 2024 were primarily driven by its business segments, with significant contributions from direct-to-patient and clinical/medical provider channels.

1. **Revenue Shift**:
- Myomo's revenue was concentrated in the direct-to-patient segment, accounting for $25.33 million, and the clinical/medical providers segment, contributing $15.49 million and $7.22 million.
- The direct-to-patient segment was the primary source of revenue, indicating a strong market presence and patient demand for Myomo's products or services.
2. **Expense Shift**:
- Myomo's expenses were also segmented, with the direct-to-patient segment incurring $25.33 million, and the clinical/medical providers segment spending $15.49 million and $7.22 million.
- The direct-to-patient segment's expenses were similar to its revenue, suggesting efficient cost management or a balanced cost structure.
- The clinical/medical providers segment had lower revenue but similar expenses to the direct-to-patient segment, which could imply different profit margins or operational strategies.

In conclusion, Myomo's revenue and expenses in Q4 2024 were characterized by strong revenue generation from the direct-to-patient segment, with the clinical/medical providers segment contributing significantly to both revenue and expenses. The company's operational focus and market strategies can be inferred from these segment-specific figures.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|MYO|MYO.A|Myomo|20240101-2024|Direct to Patient|2.5326956E7|170|
|MYO|MYO.A|Myomo|20240101-2024|Clinical/Medical Providers|4991158|170|
|MYO|MYO.A|Myomo|20240101-2024|Clinical/Medical Providers|3215323|170|
|MYO|MYO.A|Myomo|20240101-2024|Clinical/Medical Providers|1519647|170|
|MYO|MYO.A|Myomo|20240101-2024|Clinical/Medical Providers|1519647|170|
|MYO|MYO.A|Myomo|20240101-2024|Direct to Patient|2234742|170|